Fredun Pharmaceuticals Adjusts Evaluation Score Amid Mixed Technical Indicators and Strong Growth
Fredun Pharmaceuticals has undergone a recent evaluation score adjustment, reflecting changes in technical trends. The company's financial performance remains strong, with a notable annual growth rate in net sales and operating profit. Despite a slight decline in returns over the past year, profits have increased significantly.
Fredun Pharmaceuticals, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a bullish stance to a mildly bullish outlook. The company's technical indicators present a mixed picture. The MACD shows bullish momentum on a weekly basis, while the monthly perspective leans towards a mildly bullish sentiment. The Relative Strength Index (RSI) indicates bearish conditions weekly, with no significant signal on a monthly basis. Additionally, Bollinger Bands suggest a mildly bullish trend weekly, while the monthly view remains sideways. Daily moving averages are bullish, yet the KST indicates a bearish trend on a monthly scale.
In terms of financial performance, Fredun Pharmaceuticals has reported a robust annual growth rate in net sales of 32.11% and an operating profit increase of 49.33%. The company has consistently delivered positive results over the last four quarters, with net sales reaching a peak of Rs 167.41 crore. Despite a return of -5.26% over the past year, profits have risen by 33.2%, showcasing a favorable PEG ratio of 0.6.
For more insights on Fredun Pharmaceuticals and its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
